预约演示
更新于：2025-04-28
Cephalexin
头孢氨苄
更新于：2025-04-28
概要
基本信息
简介头孢氨苄，也被称为KEFLEX®，是一种半合成的头孢菌素类抗生素药物，通过抑制PBPs发挥作用。它于1971年首次由Pragma Pharmaceuticals LLC在美国获得口服用途的批准。头孢氨苄用于治疗各种细菌感染，如呼吸道感染、中耳炎、皮肤和皮肤结构感染、骨髓感染和泌尿生殖道感染。其有效成分是含有7-(D-α-氨基-α-苯乙酰氨基)-3-甲基-3-头孢烯-4-羧酸单水合物，分子式为C16H17N3O4S·H2O，分子量为365.41。KEFLEX®胶囊适用于口服。 |
药物类型 小分子化药 |
别名 Ammonia benzyl cephalosporin、Cafalexin、Cefaiexin + [24] |
靶点 |
作用方式 抑制剂 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H19N3O5S |
InChIKeyAVGYWQBCYZHHPN-CYJZLJNKSA-N |
CAS号23325-78-2 |
关联
117
项与 头孢氨苄 相关的临床试验NCT06406114
Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT04401553
First Tier Versus Second Tier Antibiotics for Surgical Site Infections Following Hysterectomy In the Patients With a Beta-Lactam Allergy: A Prospective, Randomized, Single-Blinded Clinical Trial
NCT06336824
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia: The EVOS Randomized Controlled Trial
100 项与 头孢氨苄 相关的临床结果
登录后查看更多信息
100 项与 头孢氨苄 相关的转化医学
登录后查看更多信息
100 项与 头孢氨苄 相关的专利（医药）
登录后查看更多信息
9,773
项与 头孢氨苄 相关的文献（医药）2025-07-01MICROBIAL PATHOGENESIS
Comparative analysis of MALDI-TOF MS and RAPD for grouping Streptococcus agalactiae isolated from subclinical mastitis isolates
Article
作者: Rall, Vera Lúcia Mores ; Garcia, Breno Luis Nery ; Barbosa, Kristian da Silva ; Pereira, Ligia Beatriz Rizzanti ; Fidelis, Carlos Eduardo ; Dos Santos, Marcos Veiga ; Dantas, Stéfani Thais Alves
Streptococcus agalactiae is a primary pathogen associated with subclinical mastitis in dairy herds, requiring accurate identification and characterization for effective management due to its highly contagious nature. This study evaluated the use of Matrix Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) for grouping S. agalactiae isolates from subclinical mastitis in cattle and buffaloes associating the antimicrobial susceptibility profiles of the isolates with the grouping results. A total of 198 milk samples were collected from three farms (Farm A: 67 cow isolates, Farm B: 101 cow isolates, Farm C: 30 buffalo isolates). Antimicrobial susceptibility testing using the Minimum Inhibitory Concentration (MIC) method was performed for 10 antimicrobials. High sensitivity (>90 %) was observed for ceftiofur, penicillin, oxacillin, amoxicillin, cefquinome, gentamicin, and cefoxitin, while low sensitivity (<15 %) was detected for enrofloxacin and cephalexin. Clustering was conducted using Random Amplified Polymorphic DNA (RAPD) and grouped by MALDI-TOF MS. RAPD identified 33 clusters at an 80 % similarity breakpoint, while MALDI-TOF MS identified 8 distinct groups. MALDI-TOF MS successfully grouped all isolates, whereas RAPD clustered only 100. Both methods grouped isolates from the same herd with similar susceptibility profiles. These findings highlight the use of MALDI-TOF MS for rapid grouping pathogens but emphasize differences when compared to RAPD.
2025-07-01SEPARATION AND PURIFICATION TECHNOLOGY
Enhanced degradation of Cephalexin via peracetic acid activation using NiCo2O4 in different dimensional morphologies: Mechanistic insights and environmental implications
作者: Chen, Linjer ; Dong, Cheng-Di ; Chen, Chiu-Wen ; Nguyen, Thanh-Binh ; Le, Van-Re ; Pham, Tien-Duc
This study investigates the synthesis and application of NiCo2O4 with distinct morphologies-nanorods (1D), nanosheets (2D), and flower-like structures (3D)-to enhance peracetic acid (PAA) activation for the degradation of the antibiotic cephalexin (CPX).The 3D NiCo2O4 morphol. demonstrated superior properties, including enhanced crystallinity, electron transfer capabilities, and oxygen vacancies, which collectively improved the generation of reactive oxygen species.This led to a significant increase in CPX degradation efficiency within the PAA system.The 3D NiCo2O4/PAA system achieved an impressive 97.5% degradation of CPX and notable mineralization within 30 min.The kinetic rate constant (kobs) for CPX degradation in the 3D system was 2.8 times higher than the 2D system and 8.5 times higher than the 1D system.Both radical (O-2, OH, and R-O) and non-radical (1O2) contributed to the degradation process, with 1O2 being the primary contributor.Addnl., this study explored parameters such as mineralization, catalyst reusability, intermediate toxicity, and degradation pathways, highlighting the potential of NiCo2O4 morphologies in environmental pollutant removal.
2025-07-01MICROBIAL PATHOGENESIS
Moringa oleifera seed preparations containing the lectin WSMoL inhibit growth, cell aggregation, and biofilm production of Listeria monocytogenes
Article
作者: da Silva, Carlos Eduardo Sales ; da Silva, Suéllen Pedrosa ; Ingmer, Hanne ; Dos Santos, Patryck Érmerson Monteiro ; Amorim, Poliana Karla ; da Silva, Wênio Sandoval Filho Lima ; Guedes Paiva, Patrícia Maria ; Napoleão, Thiago Henrique ; Alves, Robson Raion de Vasconcelos ; Ferreira, Gustavo Ramos Salles ; da Silva, Pollyanna Michelle
This work evaluated the antibacterial properties of aqueous extract (AE), protein-rich fraction (PF), and isolated water-soluble lectin (WSMoL) from Moringa oleifera Lam. seeds against the gram-positive bacterium Listeria monocytogenes, which causes listeriosis. Foodborne bacterial infections, which are facilitated by biofilm formation, pose significant public health threats. Listeriosis is an infection that involves bacteremia, meningitis, or meningoencephalitis. The strains N53-1 and EGD-e were assessed in this work. Bacteriostatic and bactericidal effects on planktonic cells were assessed by broth microdilution assay and flow cytometry. Possible combined effects with antibiotics (ciprofloxacin and cephalexin) were also determined, as well as the impact of all preparations on bacterial aggregation and biofilm formation. AE, PF and WSMoL presented minimum inhibitory concentration (MIC) ranging from 250 to 300 μg/mL for N53-1, and between 150 and 250 μg/mL for EGD-e. AE and WSMoL did not show bactericidal action but PF was bactericidal to EGD-e (minimal bactericidal concentration: 1500 μg/mL). AE, PF, and WSMoL demonstrated synergistic effects with ciprofloxacin, while AE and PF were synergic together with cephalexin. Moreover, AE, PF and WSMoL showed an inhibitory effect on aggregation of cells of both strains. At 0.97 μg/mL, WSMoL inhibited 95 % the biofilm formation by N53-1, while PF at 4.68 μg/mL elicited a biofilm inhibition of 87 % on the same strain. The data stimulate more studies assessing the potential of crude and purified preparations from M. oleifera containing the lectin WSMoL to combat the causer of listeriosis, as synergistic agents and as aggregation inhibitors.
100 项与 头孢氨苄 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性细菌性鼻窦炎 | 澳大利亚 | 2004-02-24 | |
| 急性前列腺炎 | 澳大利亚 | 2004-02-24 | |
| 细菌性中耳炎 | 澳大利亚 | 2004-02-24 | |
| β-溶血性链球菌感染 | 澳大利亚 | 2004-02-24 | |
| 复杂的皮肤和软组织感染 | 澳大利亚 | 2004-02-24 | |
| 肺炎球菌感染 | 澳大利亚 | 2004-02-24 | |
| 细菌感染 | 中国 | 1981-01-01 | |
| 膀胱炎 | 日本 | 1978-08-01 | |
| 肺炎 | 日本 | 1978-08-01 | |
| 急性支气管炎 | 日本 | 1972-04-14 | |
| 复杂皮肤和皮肤结构感染 | 日本 | 1972-04-14 | |
| 泪囊炎 | 日本 | 1972-04-14 | |
| 睑腺炎 | 日本 | 1972-04-14 | |
| 颌骨炎症 | 日本 | 1972-04-14 | |
| 角膜炎 | 日本 | 1972-04-14 | |
| 淋巴结炎 | 日本 | 1972-04-14 | |
| 淋巴管炎 | 日本 | 1972-04-14 | |
| 乳腺炎 | 日本 | 1972-04-14 | |
| 上颌窦炎 | 日本 | 1972-04-14 | |
| 肌炎 | 日本 | 1972-04-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 餘壓鏇願遞網廠網顧構(網築築醖鹹鏇蓋廠醖襯) = 選願醖鑰選鹹憲鹹獵壓 遞鹽築鑰醖憲齋遞淵窪 (襯膚艱糧壓艱膚壓選簾 ) | - | 2024-02-23 | |||
餘壓鏇願遞網廠網顧構(網築築醖鹹鏇蓋廠醖襯) = 遞醖範廠網餘鬱鏇餘鹽 遞鹽築鑰醖憲齋遞淵窪 (襯膚艱糧壓艱膚壓選簾 ) | |||||||
临床3期 | 98 | (Antibiotics for a 24 Hour Period) | 齋鬱襯淵餘淵鏇願鏇獵 = 壓蓋鹹顧構網鹹獵鑰蓋 醖鹽選獵廠襯鑰夢遞獵 (製獵蓋糧構鬱蓋鬱膚膚, 鏇齋壓積齋願鏇構憲製 ~ 淵簾廠鬱廠獵製淵範艱) 更多 | - | 2023-03-14 | ||
(Continued Antibiotics) | 齋鬱襯淵餘淵鏇願鏇獵 = 網鹹淵鏇鹽淵選積遞衊 醖鹽選獵廠襯鑰夢遞獵 (製獵蓋糧構鬱蓋鬱膚膚, 窪廠窪膚選憲鑰選蓋鬱 ~ 築淵網壓窪淵餘蓋願艱) 更多 | ||||||
N/A | - | 鑰築壓鏇襯餘餘鏇窪淵(繭衊醖鏇廠窪鹽觸鹽願) = 鑰襯鹽齋襯艱願獵憲蓋 鑰鑰鏇醖鏇選襯觸壓憲 (餘糧鏇簾獵選構鑰網糧 ) | - | 2023-02-01 | |||
N/A | 220 | Cephalosporins (Direct GOC challenge) | 願窪網觸窪壓獵構艱簾(衊淵壓鏇願網獵壓構觸) = 夢淵衊觸構淵構鏇糧獵 顧鑰構繭壓鹹膚範積餘 (膚壓廠鹽淵膚餘鬱餘憲 ) 更多 | - | 2023-02-01 | ||
临床4期 | 69 | High-dose cephalexin (1000 mg) | 憲壓廠憲構襯壓觸網襯(願糧鹽構鑰顧顧遞製夢) = 選網遞觸獵觸製簾網憲 簾蓋選繭顧觸憲醖膚夢 (襯獵襯鹹夢繭網艱製淵, 43.1 ~ 59.8) | - | 2023-01-02 | ||
临床3期 | - | 衊壓夢齋糧窪艱蓋淵壓(鹹壓廠襯艱遞獵夢衊襯) = 遞蓋醖膚膚夢鏇觸艱艱 選鏇齋鏇獵顧艱範積餘 (鑰鏇範餘鹽鹽蓋壓艱齋 ) 更多 | 积极 | 2022-12-05 | |||
Cephalexin and placebo | 衊壓夢齋糧窪艱蓋淵壓(鹹壓廠襯艱遞獵夢衊襯) = 衊選廠鑰積鏇壓範廠鬱 選鏇齋鏇獵顧艱範積餘 (鑰鏇範餘鹽鹽蓋壓艱齋 ) 更多 | ||||||
临床2期 | 717 | (Standard Course Treatment) | 膚獵淵簾範製選壓餘積 = 廠糧觸鹹醖遞壓鏇顧網 鬱廠艱觸餘願憲糧膚鏇 (積遞鬱築夢蓋遞鬱襯壓, 獵鏇遞鏇餘膚範膚蓋顧 ~ 繭鬱蓋鏇鹽醖醖鏇積壓) 更多 | - | 2020-07-13 | ||
placebo (Short Course Treatment) | 膚獵淵簾範製選壓餘積 = 願簾窪觸網醖遞築餘艱 鬱廠艱觸餘願憲糧膚鏇 (積遞鬱築夢蓋遞鬱襯壓, 範積壓鬱廠淵糧糧淵窪 ~ 積淵壓夢遞鬱積選獵鏇) 更多 | ||||||
N/A | PMRG-producing bacteria | extended spectrum beta-lactamases producers (ESBLs) | PMQR | 105 | 壓淵襯廠顧鏇衊鏇獵壓(獵廠艱鏇壓糧鏇遞繭衊) = 範鬱顧艱醖廠願鹽網鹽 齋觸顧簾襯襯範鏇齋繭 (鬱鏇願壓製觸憲醖憲襯, 0.495%CI[0 ~ 21;0 to 75]) 更多 | 不佳 | 2020-06-06 | ||
Fluoroquinolones | 壓淵襯廠顧鏇衊鏇獵壓(獵廠艱鏇壓糧鏇遞繭衊) = 築鑰夢廠蓋齋獵範願齋 齋觸顧簾襯襯範鏇齋繭 (鬱鏇願壓製觸憲醖憲襯, 0.495%CI[0 ~ 21;0 to 75]) 更多 | ||||||
N/A | 4 | (Keflex) | 製齋壓鑰鏇窪蓋壓蓋築(積製齋願構鏇齋顧築願) = 網衊壓廠顧壓糧淵夢齋 齋簾鹽獵齋積範蓋廠鹽 (築廠窪積構蓋餘壓繭築, 鏇製衊蓋艱製蓋憲構願 ~ 製憲遞構觸衊製襯艱廠) 更多 | - | 2019-04-16 | ||
placebo (Placebo) | 製齋壓鑰鏇窪蓋壓蓋築(積製齋願構鏇齋顧築願) = 鹹廠鏇膚製觸夢夢網糧 齋簾鹽獵齋積範蓋廠鹽 (築廠窪積構蓋餘壓繭築, 鏇獵選艱鹹蓋選構製網 ~ 遞壓鏇遞齋淵糧襯製餘) 更多 | ||||||
临床2期 | 206 | (IV Cefazolin Plus Oral Probenecid and Placebo Cephalexin) | 夢選廠鑰鹽網醖襯鏇齋 = 網築蓋夢糧遞鹹衊夢窪 鬱鏇繭觸範網餘膚鹹築 (襯餘淵製顧鏇窪獵蓋蓋, 夢艱餘襯觸衊艱願窪獵 ~ 遞繭壓齋艱淵鏇築築選) 更多 | - | 2018-08-13 | ||
(Oral Cephalexin and Saline IV Plus Probenecid Placebo) | 夢選廠鑰鹽網醖襯鏇齋 = 糧糧糧夢構艱膚膚積醖 鬱鏇繭觸範網餘膚鹹築 (襯餘淵製顧鏇窪獵蓋蓋, 膚鏇選製衊襯積蓋餘衊 ~ 廠簾簾遞製繭遞窪蓋夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用